1. Neuroprotective and antioxidant effects of ghrelin in an experimental glaucoma model
- Author
-
Can N, Catak O, Turgut B, Demir T, Ilhan N, Kuloglu T, and Ozercan IH
- Subjects
lcsh:Therapeutics. Pharmacology ,genetic structures ,lcsh:RM1-950 ,sense organs ,eye diseases - Abstract
Nagehan Can,1 Onur Catak,2 Burak Turgut,2 Tamer Demir,2 Nevin Ilhan,3 Tuncay Kuloglu,4 Ibrahim Hanifi Ozercan5 1Department of Ophthalmology, Elaziğ Training and Research Hospital, 2Department of Ophthalmology, 3Department of Biochemistry, 4Department of Histology and Embryology, 5Department of Pathology, School of Medicine, Firat University, Elaziğ, Turkey Abstract: Damage to retinal ganglion cells due to elevation of intraocular pressure (IOP) is responsible for vision loss in glaucoma. Given that loss of these cells is irreversible, neuroprotection is crucial in the treatment of glaucoma. In this study, we investigated the possible antioxidant and neuroprotective effects of ghrelin on the retina in an experimental glaucoma model. Twenty-one Sprague–Dawley rats were randomly assigned to three groups comprising seven rats each. The rats in the control group were not operated on and did not receive any treatment. In all rats in the other groups, IOP was increased by cauterizationof thelimbal veins. After creation of the IOP increase, saline 1 mL/kg orghrelin 40 µg/kg was administered intraperitoneally every day for 14 days in the vehicle control group and ghrelin groups, respectively. On day 14 of the study, the eyes were enucleated. Levels of malondialdehyde (MDA), nitric oxide (NO), and nitric oxide synthase-2 (NOS2) in anterior chamber fluid were measured. The retinas were subjected to immunohistochemistry staining for glial fibrillary acidic protein (GFAP), S-100, andvimentin expression. Mean levels of MDA, NO, and NOS2 in the aqueous humor were higher in the vehicle control group than in the control group (P0.05). Retinal TUNEL and immunohistochemistry staining in the vehicle control group showed an increase in apoptosis and expression of GFAP, S-100, and vimentin compared with the control group (P
- Published
- 2015